Trelema, 50 mg, coated tablets
Trelema, 100 mg, coated tablets
Trelema, 150 mg, coated tablets
Trelema, 200 mg, coated tablets
Lacosamide
Trelema contains the active substance lacosamide. It belongs to a group of medicines called antiepileptics, which are used to treat epilepsy.
This medicine has been prescribed by the doctor to reduce the number of seizures.
Trelema should not be taken if any of the following situations apply to the patient. In case of doubt, the doctor or pharmacist should be consulted.
Before starting to take Trelema, the doctor should be consulted if:
If any of the above situations apply to the patient (or if the patient has doubts), before taking Trelema, they should consult their doctor or pharmacist.
If Trelema is taken, the doctor should be informed about any new types of seizures or worsening of existing seizures.
If the patient takes Trelema and experiences symptoms of abnormal heartbeats (such as slow, fast, or irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), they should immediately consult their doctor (see section 4).
Trelema is not recommended for children under 2 years of age with epilepsy characterized by partial seizures or for children under 4 years of age with primary generalized tonic-clonic seizures. The efficacy and safety of Trelema in children under these ages have not been established.
The doctor or pharmacist should be informed about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
The doctor or pharmacist should be informed, in particular, about the use of the following medicines, which affect the heart:
The doctor or pharmacist should also be informed if the patient is taking any of the following medicines, as they may weaken or enhance the effect of Trelema:
If any of the above situations apply to the patient (or if the patient has doubts), before taking Trelema, they should consult their doctor or pharmacist.
For safety reasons, alcohol should not be consumed while taking Trelema.
Women of childbearing age should discuss the use of contraception with their doctor.
If the patient is pregnant or breastfeeding, or thinks they may be pregnant or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Trelema should not be taken during pregnancy, as its effect on pregnancy and the unborn child is not known.
Breastfeeding should not be done while taking Trelema, as Trelema passes into breast milk. The patient should immediately consult their doctor if they become pregnant or plan to become pregnant. The doctor will help make a decision about whether to continue taking Trelema.
Trelema should not be stopped without consulting the doctor, as this may cause the symptoms of epilepsy to return or worsen. The worsening of the mother's disease may also harm the child.
The patient should not drive a car or ride a bicycle or use any tools or operate machines until they are sure what effect the medicine has on them, as Trelema may cause dizziness or blurred vision.
This medicine should always be taken as directed by the doctor. In case of doubt, the doctor or pharmacist should be consulted. For children, other forms of this medicine may be more suitable; the doctor or pharmacist should be consulted.
Usually, treatment starts with a low dose taken daily, which the doctor will gradually increase over several weeks. After reaching the dose that is effective for the patient, the so-called maintenance dose, the patient will take the same dose every day. Trelema is intended for long-term use. The patient should take the medicine for as long as the doctor does not recommend stopping it.
The following are the usual recommended doses of Trelema for patients in different age groups and with different body weights. The doctor may prescribe a different dose if the patient has kidney or liver function disorders.
Monotherapy with Trelema
Usually, the initial dose of Trelema is 50 mg twice a day.
The doctor may also prescribe an initial dose of 100 mg of Trelema twice a day.
The doctor may increase the dose given twice a day by 50 mg every week, up to a maintenance dose of between 100 mg and 300 mg twice a day.
Combination therapy with other antiepileptic medicines
Usually, the initial dose of Trelema is 50 mg twice a day.
The doctor may increase the dose given twice a day by 50 mg every week, up to a maintenance dose of between 100 mg and 200 mg twice a day.
In the case of patients with a body weight of 50 kg or more, the doctor may decide to start treatment with a single loading dose of 200 mg. Then, after 12 hours, the patient will start taking the maintenance dose.
The dose depends on body weight. In children and adolescents with a body weight below 50 kg, treatment usually starts with the syrup form. Switching to tablets can only be done if the child can swallow the tablet and the correct dose can be achieved using different tablet strengths. The doctor will prescribe the most suitable form of the medicine for the child.
In case of taking a higher dose of Trelema than prescribed, the doctor should be contacted immediately. The patient should not try to drive a car.
The patient may experience:
In case of any further doubts about the use of this medicine, the doctor or pharmacist should be consulted.
Like all medicines, Trelema can cause side effects, although not everybody gets them.
Neurological symptoms, such as dizziness, may be stronger after taking a single loading dose.
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
Additional side effects in children included: fever, runny nose (nasopharyngitis), sore throat (pharyngitis), decreased appetite, behavioral changes, the child does not behave as usual (abnormal behavior), and lack of energy (lethargy). Drowsiness is a very common side effect in children and may occur in more than 1 in 10 children.
If any side effects occur, including any side effects not listed in the leaflet, the doctor or pharmacist should be informed. Side effects can be reported directly to:
Department for Monitoring of Adverse Reactions of Medicinal Products
Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181 C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
Thanks to the reporting of side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiration date stated on the carton after EXP.
The expiration date refers to the last day of the month stated.
There are no special precautions for storing the medicine.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer needed. This will help protect the environment.
Tablet coating
Polyvinyl alcohol
Macrogol 3350
Titanium dioxide (E 171)
Talc
Colorants:
50 mg, coated tablets:
indigo carmine (E 132), iron oxide red (E 172), iron oxide black (E 172)
100 mg, coated tablets:
iron oxide yellow (E 172)
150 mg, coated tablets:
iron oxide yellow (E 172), iron oxide red (E 172), iron oxide black (E 172)
200 mg, coated tablets:
indigo carmine (E 132)
Trelema, 50 mg, coated tablets
Pink, oval, biconvex, coated tablets with a score line on both sides.
The tablet can be divided into equal doses.
Trelema, 100 mg, coated tablets
Yellow, oval, biconvex, coated tablets with a score line on both sides.
The tablet can be divided into equal doses.
Trelema, 150 mg, coated tablets
Brown, oval, biconvex, coated tablets with a score line on both sides.
The tablet can be divided into equal doses.
Trelema, 200 mg, coated tablets
Blue, oval, biconvex, coated tablets with a score line on both sides.
The tablet can be divided into equal doses.
Trelema is available in the following pack sizes:
10, 14, 20, 28, 30, 40, 56, 60, 84, 90, 100, 112, 120, and 168 coated tablets in PVC/Aluminum or PVC/PVdC/Aluminum blisters.
Not all pack sizes may be marketed.
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria
Delorbis Pharmaceuticals Ltd.
2643 Ergates, Lefkosia
Cyprus
G.L. PHARMA POLAND Sp. z o.o.
Al. Jana Pawła II 61/313
01-031 Warsaw, Poland
Phone: 022/636 52 23; 636 53 02
e-mail: biuro@gl-pharma.pl
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.